High vascular endothelial growth factor gene expression predicts poor outcome in patients with non-luminal A breast cancer

Sa‑Nguanraksa,Doonyapat; Chuangsuwanich,Tuenjai; Pongpruttipan,Tawatchai; O‑Charoenrat,Pornchai

doi:10.3892/mco.2015.574

September-2015 Volume 3 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

September-2015 Volume 3 Issue 5

Full Size Image

Article

High vascular endothelial growth factor gene expression predicts poor outcome in patients with non-luminal A breast cancer

Authors:
- Doonyapat Sa‑Nguanraksa
- Tuenjai Chuangsuwanich
- Tawatchai Pongpruttipan
- Pornchai O‑Charoenrat
View Affiliations / Copyright

Affiliations: Division of Head, Neck and Breast Surgery, Department of Surgery, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand, Department of Pathology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
Pages: 1103-1108
|
Published online on: June 9, 2015

https://doi.org/10.3892/mco.2015.574
Expand metrics +

Abstract

Breast cancer is the most frequent type of cancer among women worldwide. Vascular endothelial growth factor (VEGF), the key modulator of angiogenesis, has been implicated in breast cancer susceptibility and aggressiveness. VEGF expression was determined in 99 breast cancer tissue samples using reverse transcription‑polymerase chain reaction and the human epidermal growth factor receptor 2 (HER2) status was determined by immunohistochemistry. Subsequently, the associations of VEGF, HER2 and hormone receptor status with clinicopathological data were evaluated. High VEGF expression was found to be significantly correlated with the presence of lymphovascular invasion. In hormone receptor‑positive/HER2‑positive, HER2‑positive and triple‑negative breast cancer, high VEGF expression was correlated with the presence of axillary nodal metastasis and lower overall survival rates. Therefore, the assessment of the VEGF status along with the hormone receptor and HER2 status may help identify high‑risk patients who may benefit from anti-VEGF treatment.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	National Cancer Institute: Information Technology Division, . http://www.nci.go.th/th/cancer_record/cancer_rec1.htmlAccessed. November 1–2014
3	Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 82:4–6. 1990. View Article : Google Scholar : PubMed/NCBI
4	Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
5	Burstein HJ, Chen YH, Parker LM, et al: VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res. 14:7871–7877. 2008. View Article : Google Scholar : PubMed/NCBI
6	Miles DW, de Haas SL, Dirix LY, et al: Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer. 108:1052–1060. 2013. View Article : Google Scholar : PubMed/NCBI
7	Schneider BP, Wang M, Radovich M, et al: ECOG 2100: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 26:4672–4678. 2008. View Article : Google Scholar : PubMed/NCBI
8	O-Charoenrat P, Rhys-Evans P, Modjtahedi H and Eccles SA: Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells. Clin Exp Metastasis. 18:155–161. 2000. View Article : Google Scholar : PubMed/NCBI
9	Sa-Nguanraksa D and O-Charoenrat P: The role of vascular endothelial growth factor a polymorphisms in breast cancer. Int J Mol Sci. 13:14845–14864. 2012. View Article : Google Scholar : PubMed/NCBI
10	Zheng S, Song QK, Ren Y, et al: The characteristics of breast cancer subtypes: Implications for treatment guidelines and individualized treatment strategies in China. Appl Immunohistochem Mol Morphol. 22:383–389. 2014. View Article : Google Scholar : PubMed/NCBI
11	Dawood S, Hu R, Homes MD, Collins LC, Schnitt SJ, Connolly J, Colditz GA and Tamimi RM: Defining breast cancer prognosis based on molecular phenotypes: Results from a large cohort study. Breast Cancer Res Treat. 126:185–192. 2011. View Article : Google Scholar : PubMed/NCBI
12	Linderholm B, Bergqvist J, Hellborg H, Johansson U, Linderholm M, von Schoultz E, Elmberger G, Skoog L and Bergh J: Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor. Med Oncol. 26:480–490. 2009. View Article : Google Scholar : PubMed/NCBI
13	Berns EM, Klijn JG, Look MP, et al: Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer. Clin Cancer Res. 9:1253–1258. 2003.PubMed/NCBI
14	Rydén L, Stendahl M, Jonsson H, Emdin S, Bengtsson NO and Landberg G: Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response. Breast Cancer Res Treat. 89:135–143. 2005. View Article : Google Scholar : PubMed/NCBI
15	Liu Y, Tamimi RM, Collins LC, Schnitt SJ, Gilmore HL, Connolly JL and Colditz GA: The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: Results from the Nurses' Health Study. Breast Cancer Res Treat. 129:175–184. 2011. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

High vascular endothelial growth factor gene expression predicts poor outcome in patients with non-luminal A breast cancer

This article is mentioned in:

Abstract

Figure 1

Related Articles